256 related articles for article (PubMed ID: 28093238)
1. A model of the mitochondrial basis of bipolar disorder.
Morris G; Walder K; McGee SL; Dean OM; Tye SJ; Maes M; Berk M
Neurosci Biobehav Rev; 2017 Mar; 74(Pt A):1-20. PubMed ID: 28093238
[TBL] [Abstract][Full Text] [Related]
2. Attenuation of mania-like behavior in Na(+),K(+)-ATPase α3 mutant mice by prospective therapies for bipolar disorder: melatonin and exercise.
Kirshenbaum GS; Burgess CR; Déry N; Fahnestock M; Peever JH; Roder JC
Neuroscience; 2014 Feb; 260():195-204. PubMed ID: 24342563
[TBL] [Abstract][Full Text] [Related]
3. Mitochondrial dysfunction in bipolar disorder: Evidence, pathophysiology and translational implications.
Scaini G; Rezin GT; Carvalho AF; Streck EL; Berk M; Quevedo J
Neurosci Biobehav Rev; 2016 Sep; 68():694-713. PubMed ID: 27377693
[TBL] [Abstract][Full Text] [Related]
4. Mitochondrial dysfunction as a critical event in the pathophysiology of bipolar disorder.
Scaini G; Andrews T; Lima CNC; Benevenuto D; Streck EL; Quevedo J
Mitochondrion; 2021 Mar; 57():23-36. PubMed ID: 33340709
[TBL] [Abstract][Full Text] [Related]
5. Increased oxidative stress in the mitochondria isolated from lymphocytes of bipolar disorder patients during depressive episodes.
Valvassori SS; Bavaresco DV; Feier G; Cechinel-Recco K; Steckert AV; Varela RB; Borges C; Carvalho-Silva M; Gomes LM; Streck EL; Quevedo J
Psychiatry Res; 2018 Jun; 264():192-201. PubMed ID: 29653348
[TBL] [Abstract][Full Text] [Related]
6. Glycogen synthase kinase-3β in patients with bipolar I disorder: results from a prospective study.
Jacoby AS; Munkholm K; Vinberg M; Joaquim HG; Talib LL; Gattaz WF; Kessing LV
Bipolar Disord; 2016 Jun; 18(4):334-41. PubMed ID: 27325150
[TBL] [Abstract][Full Text] [Related]
7. The circadian system of patients with bipolar disorder differs in episodes of mania and depression.
Nováková M; Praško J; Látalová K; Sládek M; Sumová A
Bipolar Disord; 2015 May; 17(3):303-14. PubMed ID: 25359533
[TBL] [Abstract][Full Text] [Related]
8. Comparison of cytokine levels in depressed, manic and euthymic patients with bipolar disorder.
Brietzke E; Stertz L; Fernandes BS; Kauer-Sant'anna M; Mascarenhas M; Escosteguy Vargas A; Chies JA; Kapczinski F
J Affect Disord; 2009 Aug; 116(3):214-7. PubMed ID: 19251324
[TBL] [Abstract][Full Text] [Related]
9. Mitochondrial Dysfunctions in Bipolar Disorder: Effect of the Disease and Pharmacotherapy.
Cikankova T; Sigitova E; Zverova M; Fisar Z; Raboch J; Hroudova J
CNS Neurol Disord Drug Targets; 2017; 16(2):176-186. PubMed ID: 27978794
[TBL] [Abstract][Full Text] [Related]
10. Mitochondrial dysfunction and psychiatric disorders.
Rezin GT; Amboni G; Zugno AI; Quevedo J; Streck EL
Neurochem Res; 2009 Jun; 34(6):1021-9. PubMed ID: 18979198
[TBL] [Abstract][Full Text] [Related]
11. Elevated serum superoxide dismutase and thiobarbituric acid reactive substances in different phases of bipolar disorder and in schizophrenia.
Kunz M; Gama CS; Andreazza AC; Salvador M; Ceresér KM; Gomes FA; Belmonte-de-Abreu PS; Berk M; Kapczinski F
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Oct; 32(7):1677-81. PubMed ID: 18657586
[TBL] [Abstract][Full Text] [Related]
12. Structure-based design leads to the identification of lithium mimetics that block mania-like effects in rodents. possible new GSK-3beta therapies for bipolar disorders.
Kozikowski AP; Gaisina IN; Yuan H; Petukhov PA; Blond SY; Fedolak A; Caldarone B; McGonigle P
J Am Chem Soc; 2007 Jul; 129(26):8328-32. PubMed ID: 17552518
[TBL] [Abstract][Full Text] [Related]
13. Purinergic system dysfunctions in subjects with bipolar disorder: A comparative cross-sectional study.
Bartoli F; Crocamo C; Dakanalis A; Brosio E; Miotto A; Capuzzi E; Clerici M; Carrà G
Compr Psychiatry; 2017 Feb; 73():1-6. PubMed ID: 27837679
[TBL] [Abstract][Full Text] [Related]
14. Increased uric acid levels in bipolar disorder subjects during different phases of illness.
Albert U; De Cori D; Aguglia A; Barbaro F; Bogetto F; Maina G
J Affect Disord; 2015 Mar; 173():170-5. PubMed ID: 25462413
[TBL] [Abstract][Full Text] [Related]
15. The many roads to mitochondrial dysfunction in neuroimmune and neuropsychiatric disorders.
Morris G; Berk M
BMC Med; 2015 Apr; 13():68. PubMed ID: 25889215
[TBL] [Abstract][Full Text] [Related]
16. Bipolar II disorder : epidemiology, diagnosis and management.
Benazzi F
CNS Drugs; 2007; 21(9):727-40. PubMed ID: 17696573
[TBL] [Abstract][Full Text] [Related]
17. A meta-analysis of blood cytokine network alterations in psychiatric patients: comparisons between schizophrenia, bipolar disorder and depression.
Goldsmith DR; Rapaport MH; Miller BJ
Mol Psychiatry; 2016 Dec; 21(12):1696-1709. PubMed ID: 26903267
[TBL] [Abstract][Full Text] [Related]
18. Differential mitochondrial DNA copy number in three mood states of bipolar disorder.
Wang D; Li Z; Liu W; Zhou J; Ma X; Tang J; Chen X
BMC Psychiatry; 2018 May; 18(1):149. PubMed ID: 29801445
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of plasma antioxidant levels during different phases of illness in adult patients with bipolar disorder.
De Berardis D; Conti CM; Campanella D; Carano A; Di Giuseppe B; Valchera A; Tancredi L; Serroni N; Pizzorno AM; Fulcheri M; Gambi F; Sepede G; Moschetta FS; Salerno RM; Ferro FM
J Biol Regul Homeost Agents; 2008; 22(3):195-200. PubMed ID: 18842173
[TBL] [Abstract][Full Text] [Related]
20. Unipolar mania: a necessary diagnostic concept.
Angst J; Grobler C
Eur Arch Psychiatry Clin Neurosci; 2015 Jun; 265(4):273-80. PubMed ID: 25631618
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
